While a direct link between the PI3K pathway and CDK4/6 inhibition in other hormone receptor-sensitive cancers like EC is not yet identified, preclinical evidence shows the potential synergy of combining these two pathway inhibitors in hormone receptor-positive/HER2-negative breast cancer cell line models [67]. Here, NR4A1 is linked to cancer.